Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell

Completed

Conditions studied: Leukemia, Leukemia, Lymphoblastic, Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, HIV Infections, HIV Associated Lymphoma, HIV Disease; Lymphoma

In brief

This protocol will develop an observational cohort of PLWH who have been or are being treated with CAR19 therapy outside of an AMC clinical trial. Following regulatory approval of this protocol, sites will be asked to capture information of participants, who carry a diagnosis of HIV disease AND received CAR19 therapy outside of a clinical trial between August 30, 2017 and August 31, 2021. Data captured will include data points are available as part of standard of care for participants undergoing CAR19 therapy. AMC investigators, as well as non-AMC investigators will identify eligible participants to the CIBMTR, who in turn will provide the AMC statistical center with de-identified data

Key facts

Study ID

NCT05784415

Run by

AIDS Malignancy Consortium

People needed

30

Starts

2021-05-22

Expected to finish

2024-11-14

Last updated by the study team

2026-02-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented history of HIV infection
• Received CD19-directed CAR T cell therapy for acute lymphoblastic leukemia, diffuse large B-cell lymphoma, high-grade B-cell lymphoma, transformed follicular lymphoma, or primary mediastinal B-cell lymphoma
• Age ≥ 18 years

You may not qualify if…

• Prior treatment with any CAR T cell therapy

Where it is running

• Pennsylvania Hospital — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.